Alexion, AstraZeneca Rare Disease To Acquire LogicBio Therapeutics To Accelerate Growth In Genomic Medicine
October 04, 2022
October 04, 2022
WILMINGTON, Delaware, Oct. 4 -- AstraZeneca, a biopharmaceutical company, issued the following news release on Oct. 3, 2022:
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio(R) Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion's growth in genomic medicines through LogicBio's unique technology, experience . . .
Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio(R) Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion's growth in genomic medicines through LogicBio's unique technology, experience . . .